Part 1: Why test?
Dr Bernard Jansen speaks to ecancer at EMUC 2019 in Vienna about PSMA PET imaging.
He explains why scanning earlier for recurrence might be an important topic to pursue.
Dr Jansen explains his methods, and suggests where the guidelines might want to revaluate.
Part 1: Why test?
BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer
SABCS 2025: Latest developments in multigene testing in early breast cancer
New classification for identifying HR myeloma based on cytogenetic abnormalities
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Best practice in HRRm testing in patients with metastatic prostate cancer
Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems
SABCS 2023: Latest breast cancer diagnostics guidelines
Genomic testing: Awareness and effective communication between healthcare professionals and patients